{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-022974","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.546589+00:00","generated_at":"2026-05-17T15:30:08.933432+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"IMDX Q2 rev $518K, net loss $9.7M; FDA on track for GraftAssureDx submission by year-end","bullets":["Revenue $518K vs $104K YoY; gross margin 67.6%, up from 62% in Q1.","Net loss $9.7M ($0.30/sh); non-GAAP operating loss $5.98M.","Cash $26.0M; quarterly cash spend ~$6M, in line with target.","FDA submission for GraftAssureDx on track for end-2025; marketing authorization expected mid-2026.","First RUO kit sale to Swiss hospital; Medicare boost to $2,753/test."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-022974","json":"https://secwatch.observer/filing/0001641172-25-022974.json","markdown":"https://secwatch.observer/filing/0001641172-25-022974.md","text":"https://secwatch.observer/filing/0001641172-25-022974.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000164117225022974/0001641172-25-022974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000164117225022974/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:30:08.933432+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}